Trials / Terminated
TerminatedNCT02654041
Study of Induction of Hypothyroxinemia Adjunct to Conventional Therapies in GBM Patients
Phase II, Open-label, Prospective, Single-arm, Single-center Study of Induction of Hypothyroxinemia Adjunct to Conventional Therapies in GBM Patients
- Status
- Terminated
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 3 (actual)
- Sponsor
- Musli Thyropeutics Ltd. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The objective of the study is to assess the safety and efficacy of treatment with hypothyroxinemia adjunct to conventional therapies in GBM patients.
Detailed description
Since T4 (thyroxine) is a potent growth factor in numerous cancer types, the interventional approach will be to achieve thyroxine deprivation (hypothyroxinemia).This can be achieved by using a dual approach: T3 and methimazole to provide longer term inhibition of thyroid hormone synthesis.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Combined T3 and Methimazole treatment | Oral administration of T3 and Methimazole |
Timeline
- Start date
- 2016-03-01
- Primary completion
- 2017-06-01
- Completion
- 2017-06-01
- First posted
- 2016-01-13
- Last updated
- 2018-03-22
Locations
1 site across 1 country: Israel
Source: ClinicalTrials.gov record NCT02654041. Inclusion in this directory is not an endorsement.